AI assistant
Sending…
Compass Therapeutics, Inc. — Director's Dealing 2022
Apr 28, 2022
32588_dirs_2022-04-28_003666da-f19b-4134-998f-9c3378c75a59.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Compass Therapeutics, Inc. (CMPX)
CIK: 0001738021
Period of Report: 2022-04-26
Reporting Person: Chiniara Ellen (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-04-26 | Stock Option (Right to Buy) | $1.51 | A | 45000 | Acquired | 2032-04-25 | Common Stock (45000) | Direct |
Footnotes
F1: This option vests in substantially equal monthly installments over four years.
More from Compass Therapeutics, Inc.
Interim / Quarterly Report
2026
May 5
Regulatory Filings
2026
May 5
Annual Report
2026
Apr 29
Proxy Solicitation & Information Statement
2026
Apr 29
Regulatory Filings
2026
Apr 27
Director's Dealing
2026
Feb 10
Director's Dealing
2026
Jan 12
Regulatory Filings
2026
Jan 8
Regulatory Filings
2026
Jan 6
Director's Dealing
2026
Jan 5